Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2020 07:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences Appoints Neil Graham, M.D., M.B.B.S., M.P.H., as Chief Development Officer

CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
March 05, 2020 07:00 ET | Source: Evelo Biosciences, Inc.

Evelo Announces Issuance of U.S. Patent Covering Use of Proprietary Bifidobacterium animalis ssp. lactis Strain for Treating Cancer

CAMBRIDGE, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
March 02, 2020 07:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases

CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
February 25, 2020 07:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences to Present at 40th Annual Cowen Health Care Conference

CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
February 13, 2020 07:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights

—Strong 2019 marked by clinical data that validates platform——Lead inflammation candidate EDP1815 showed positive clinical data across two separate cohorts——EDP1815 Phase 2 study initiation expected...
February 06, 2020 08:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020

CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
January 10, 2020 07:00 ET | Source: Evelo Biosciences, Inc.

Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline to Registration

-- EDP1815 Phase 2 Interim Data in Psoriasis Expected by Year-End 2020 -- CAMBRIDGE, Mass., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology...
December 05, 2019 07:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences Appoints Juan Andres to Board of Directors

CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
November 13, 2019 08:01 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences to Present at the Stifel 2019 Healthcare Conference

CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
November 08, 2019 07:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences to Present Preclinical Data from its EDP1503 Oncology Program at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting

CAMBRIDGE, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right